Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicsight partners Toshiba for Japan focus

This article was originally published in Clinica

Executive Summary

Computer-aided design (CAD) specialist Medicsight and Toshiba Medical Systems have signed a preliminary commercial agreement to make the former's MedicRead Colon and ColonCAD software available in Japan. Financials details of the collaboration were not disclosed, but London, UK-based Medicsight did say that the two companies would work towards MHLW (Ministry of Health, Labour and Welfare) approval of the technology through Toshiba's system integration subsidiary. The MedicRead Colon and ColonCAD software are designed to aid radiologists in the identification of colorectal polyps and tumours during early stages, thus enhancing the chance of successful treatment. Medicsight and Toshiba have an established relationship in the field of virtual colonoscopy, as both firms are also working together in an initiative to help radiologists and gastroenterologists use software to interpret virtual colonoscopy/CT colonography images for more detailed evaluation. Medicsight said that this initiative will also continue through 2008 and beyond.

You may also be interested in...

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts